<DOC>
	<DOCNO>NCT01982253</DOCNO>
	<brief_summary>To evaluate efficacy fasiglifam 25 mg twice daily ( BID ) fasiglifam 50 mg daily ( QD ) glycemic control adult type 2 diabetes inadequately control diet exercise alone .</brief_summary>
	<brief_title>Fasiglifam 25 mg BID vs 50 mg QD</brief_title>
	<detailed_description>The drug test study call fasiglifam . Fasiglifam test treat people diabetes . This study look glycemic control people take fasiglifam . The study enroll approximately 400 patient . Participants randomly assign ( chance ) one three treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Fasiglifam 25 mg twice day - Fasiglifam 50 mg daily - Placebo ( dummy inactive pill ) - tablet look like study drug active ingredient . All participant ask take one tablet twice day throughout study . All participant ask record time symptom hypoglycemia diary . This multi-center trial conduct worldwide . The overall time participate study 18 week . Participants make 9 visit clinic . Due potential concern liver safety , balance , benefit treat patient fasiglifam ( TAK-875 ) outweigh potential risk . For reason , Takeda decide voluntarily terminate development activity fasiglifam .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Is male female 18 year age old historical diagnosis Type 2 Diabetes Mellitus ( T2DM ) . 4 . Has glycosylated hemoglobin ( HbA1c ) level ≥7.0 % ≤10.0 % fasting plasma glucose ( FPG ) ≤270 mg/dL ( 15.0 mmol/L ) Screening Visit . 5 . Has treat diet exercise receive treatment antidiabetic agent within 12 week prior Screening Visit ( Exception : patient receive antidiabetic therapy ≤7 day total within 2 month prior Screening Visit ) . 6 . Has body mass index ( BMI ) ≤45 kg/m^2 Screening . 7 . If regularly use , nonexcluded medication , must stable dose least 4 week prior Screening Visit . However , need ( PRN ) use prescription overthecounter medication allow discretion investigator . 8 . Is able willing monitor glucose home glucose monitor consistently record blood glucose concentration complete subject diary . 9 . A female childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception signing inform consent throughout duration study 30 day last dose study drug . 1 . Has receive investigational compound within 30 day prior Screening Visit receive investigational antidiabetic drug within 3 month prior Screening Visit . 2 . Was randomize previous fasiglifam study . 3 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . Has donate receive blood product within 12 week prior Screening plan donate blood study . 5 . Has hemoglobin ≤12 g/dL ( ≤120 g/L ) males ≤10 g/dL ( ≤100 g/L ) females Screening . 6 . Has systolic blood pressure ≥160 mm Hg diastolic pressure ≥95 mm Hg Screening 7 . Has history cancer remission &lt; 5 year prior Screening . A history basal cell carcinoma stage 1 squamous cell carcinoma skin allow . 8 . Has alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) level &gt; 2.0× upper limit normal ( ULN ) Screening . 9 . Has total bilirubin level great ULN Screening . Exception : patient document Gilbert 's syndrome patient allow elevated bilirubin level per investigator 's discretion . 10 . Has serum creatinine ≥1.5 mg/dL ( ≥133μmol/L ) ( male ) ≥1.4 mg/dL ( ≥124 μmol/L ) ( female ) and/or estimate glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73m^2 Screening . 11 . Has uncontrolled thyroid disease determine investigator . 12 . Has history laser treatment proliferative diabetic retinopathy within 6 month prior Screening . 13 . Had gastric banding , gastric bypass surgery within one year prior Screening . 14 . Has know history infection human immunodeficiency virus ( HIV ) , hepatitis B virus , hepatitis C virus . 15 . Had coronary angioplasty , coronary stent placement , coronary bypass surgery , myocardial infarction , unstable angina pectoris , clinically significant abnormal electrocardiogram ( ECG ) , cerebrovascular accident transient ischemic attack within 3 month prior Screening . 16 . Has history hypersensitivity , allergy , anaphylactic reaction ( ) component fasiglifam . 17 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 2 year prior Screening . 18 . Received excluded medication prior Screening Visit expect receive excluded medication . 19 . If female , pregnant ( confirmed laboratory testing , ie , serum/urine human chorionic gonadotropin ( hCG ) , females childbearing potential ) lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . 20 . The subject unable understand verbal write English language certify translation approve informed consent available . 21 . The subject physical psychiatric disease condition judgment investigator may affect life expectancy may make difficult successfully manage follow subject accord protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>